Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method

Background Autosomal dominant polycystic kidney disease (ADPKD) causes about 10% of cases of end stage renal disease. Disease progression rate is heterogeneous. Tolvaptan is presently the only specific therapeutic option to slow kidney function decline in adults at risk of rapidly progressing ADPKD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of nephrology 2022-11, Vol.35 (8), p.2109-2118
Hauptverfasser:	Rodríguez, Rosa Miquel, Luis-Lima, Sergio, Fernandez, Juan Manuel, Gómez, María Vanesa Pérez, Toledo, Beatriz González, Cobo, Marian, Delgado-Mallén, Patricia, Escamilla, Beatriz, Marco, Cristina Oramas, Estupiñán, Sara, Perera, Coriolano Cruz, Mena, Natalia Negrín, Martín, Laura Díaz, Reyes, Sergio Pitti, González, Ibrahim Hernández, González-Rinne, Federico, González-Delgado, Alejandra, Ferrer-Moure, Carmen, Zulueta, Begoña López-Botet, Torres, Armando, Rodriguez Pérez, Jose Carlos, Gaspari, Flavio, Ortiz, Alberto, Porrini, Esteban
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Creatinine Glomerular Filtration Rate Humans Medicine Medicine & Public Health Nephrology original original Article Polycystic Kidney, Autosomal Dominant - complications Polycystic Kidney, Autosomal Dominant - diagnosis Polycystic Kidney, Autosomal Dominant - drug therapy Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - etiology Tolvaptan - therapeutic use Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!